Zacks: Brokerages Expect Agios Pharmaceuticals (AGIO) to Post -$1.66 EPS

Equities research analysts forecast that Agios Pharmaceuticals (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.66) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Agios Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.69) and the highest estimate coming in at ($1.62). Agios Pharmaceuticals posted earnings of ($1.78) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6.7%. The firm is expected to issue its next earnings results on Tuesday, August 14th.

On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.51) per share for the current year, with EPS estimates ranging from ($6.73) to ($6.40). For the next financial year, analysts anticipate that the company will post earnings of ($4.83) per share, with EPS estimates ranging from ($6.30) to ($0.89). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Agios Pharmaceuticals.

Get Agios Pharmaceuticals alerts:

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The business’s revenue for the quarter was down 16.2% compared to the same quarter last year. During the same period last year, the company posted ($1.56) EPS.

A number of analysts have recently weighed in on the company. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. SunTrust Banks set a $115.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 17th. Finally, BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $88.40.

NASDAQ:AGIO opened at $86.99 on Wednesday. The company has a market cap of $4.95 billion, a PE ratio of -12.89 and a beta of 1.98. Agios Pharmaceuticals has a fifty-two week low of $45.96 and a fifty-two week high of $89.33.

In related news, insider Steven L. Hoerter sold 2,050 shares of the firm’s stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $85.95, for a total value of $176,197.50. Following the completion of the sale, the insider now owns 2,050 shares of the company’s stock, valued at $176,197.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Bowden sold 2,000 shares of the firm’s stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the sale, the insider now directly owns 2,881 shares of the company’s stock, valued at approximately $245,173.10. The disclosure for this sale can be found here. Insiders sold 62,950 shares of company stock valued at $5,102,838 in the last ninety days. 3.02% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Profund Advisors LLC raised its holdings in Agios Pharmaceuticals by 4.3% in the first quarter. Profund Advisors LLC now owns 15,875 shares of the biopharmaceutical company’s stock worth $1,298,000 after purchasing an additional 649 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 762 shares in the last quarter. California Public Employees Retirement System raised its holdings in Agios Pharmaceuticals by 3.4% in the third quarter. California Public Employees Retirement System now owns 36,100 shares of the biopharmaceutical company’s stock worth $2,410,000 after purchasing an additional 1,200 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Agios Pharmaceuticals by 15.7% in the first quarter. State of Wisconsin Investment Board now owns 9,904 shares of the biopharmaceutical company’s stock worth $810,000 after purchasing an additional 1,345 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares in the last quarter. Institutional investors and hedge funds own 82.13% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)